We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

AI Tool Merges Patient Data with Blood Test Results to Detect Heart Failure

By LabMedica International staff writers
Posted on 20 Jun 2022
Print article
Image: AI can be better at spotting heart failure than current tests (Photo courtesy of Pexels)
Image: AI can be better at spotting heart failure than current tests (Photo courtesy of Pexels)

Acute heart failure is a life-threatening condition caused when the heart is suddenly unable to pump blood around the body. It affects millions of people and accounts for a large percentage of all unplanned hospital admissions. Diagnosis is difficult because symptoms, such as shortness of breath and leg swelling, occur in many other illnesses. Previous research has shown that patients who are diagnosed quickly benefit the most from treatment. Now, research suggests that using artificial intelligence (AI) can help diagnose acute heart failure with more accuracy than current blood tests alone.

The research conducted by The University of Edinburgh (Edinburgh, UK) found that using AI to combine patient data with results from a test for levels of a protein made by the heart could help doctors spot heart failure sooner and improve patient care. Researchers combined data from 10,369 patients with suspected acute heart failure to develop a tool - called CoDE-HF – to inform clinicians’ decisions. CoDE-HF uses AI to combine routinely collected patient information with results from a blood test for the heart protein NT-proBNP to produce an estimate of whether they suffered heart failure. The current recommended diagnosis method is to test to see if levels of NT-proBNP are below a certain cut-off value, but this is not widely used as levels can vary depending on an individual’s age, weight and other health conditions.

As well as spotting acute heart failure more accurately than heart protein blood tests on their own, CoDE-HF was especially precise in difficult to diagnose patient groups - such as older people and those with pre-existing medical conditions. The team is currently conducting further studies to understand how this decision-support tool will work in the hospital environment and influence patient outcomes.

“Heart failure can be a very challenging diagnosis to make in practice. We have shown that CoDE-HF, our decision-support tool, can substantially improve the accuracy of diagnosing heart failure compared to current blood tests,” said Dr. Ken Lee, cardiology specialist registrar and clinical lecturer at the University of Edinburgh.

“Our study demonstrates that the application of artificial intelligence in healthcare has major potential to help doctors deliver more personalized patient care,” added Dimitrios Doudesis, research fellow and data scientist at the University of Edinburgh.

“The application of artificial intelligence in decision-support tools as CoDE-HF to deliver more personalized care is particularly important given our ageing patient population who are living longer with more pre-existing medical conditions. We are currently conducting further studies to identify ways to implement CoDE-HF effectively in routine care,” stated Professor Nicholas Mills, British Heart Foundation professor of cardiology at the University of Edinburgh and consultant cardiologist.

Related Links:
The University of Edinburgh 

Automated ELISA-IFA-BLOT Processor AP 22
Gold Supplier
SARS-COV-2 PLUS UK Real Time PCR kit
ELISA & CLIA Analyzer
Autoplex Gen2
Modular Clinical Chemistry Analyzer
CMD 800X1/CMD 800iX1

Print article


Molecular Diagnostics

view channel
Image: DNA test for Monkeypox (Photo courtesy of Anitoa Systems)

Turn-Key PCR Solution Enables On-Site, Near Patient Testing for Monkeypox Virus

The World Health Organization has reported that over 2,100 people in 42 countries have been diagnosed with Monkeypox as of June 15, nearly all during the past two months. This makes it important for healthcare... Read more


view channel
Image: Fujirebio has acquired ADx NeuroSciences for 40 million Euros (Photo courtesy of Pexels)

Fujirebio Acquires ADx NeuroSciences to Speed Development of Neurodegenerative Diseases Diagnostic Tests

Fujirebio Holdings, Inc. (Tokyo, Japan) has announced the acquisition of ADx NeuroSciences (Gent, Belgium) for EUR 40 million in a deal that is expected to close in July 2022, pending the satisfaction... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.